The Lankenau Institute for Medical Research (LIMR), part of Main Line Health, has been awarded three grants to support ongoing clinical research. The National Institutes of Health (NIH) awarded two grants totaling $3.85 million and the Lupus Research Institute (LRI) granted LIMR $300,000.
“We are extremely excited about the research opportunities that are now possible with the support of the NIH and LRI,” states George Prendergast, PhD, President and CEO of Lankenau Institute for Medical Research. “Our ongoing pancreatic and skin cancer research as well as developing lupus treatments will be greatly supported through these grants.”
The first grant from NIH, of $1.97 million, is to investigate the IDO pathway as a possible treatment target in pancreatic cancer. This targeted therapy for pancreatic cancer under, the direction of Dr. George Prendergast and Dr. Alexander Muller, Associate Professor at LIMR, is reportedly showing encouraging early results. The second NIH grant, of $1.88 million, is to study polyamine-stimulated stem cell recruitment in arsenic-induced skin cancer, under the direction of Susan K. Gilmour, PhD, Professor at LIMR.
In addition, the Lupus Research Institute granted LIMR $300,000, based on preliminary data generated by Dr. Laura Mandik-Nayak, associate professor at LIMR, securing a Lankenau Women’s Board award. Dr. Mandik-Nayak’s grant could lead to a new approach for the prevention and treatment of lupus and its related symptoms.